Jane Street
OBIO icon

Jane Street’s Orchestra BioMed OBIO Stock Holding History

Jane Street’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65K Buy
15,300
+1,400
+10% +$5.96K ﹤0.01% 10868
2025
Q4 		$57.7K Buy
+13,900
New +$56.1K ﹤0.01% 10457

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jane Street's OBIO Position: Q1 2026 in Review

Jane Street reduced its Orchestra BioMed (OBIO) stake by 68% in Q1 2026, selling an estimated $503K and leaving 55,680 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #9758.

Jane Street first reported a position in OBIO in Q2 2024 and has held it in 6 quarters since. The position peaked at $721K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Jane Street held 55,680 shares of Orchestra BioMed worth $237K as of Q1 2026.
  • Jane Street sold 118,085 Orchestra BioMed shares in Q1 2026, an estimated $503K.
  • Orchestra BioMed made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #9758 holding.
  • Jane Street first reported a position in Orchestra BioMed in Q2 2024 and has held it in 6 quarters since.
  • Jane Street's Orchestra BioMed position peaked at $721K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.